Aclarion Announces Commercial Agreement with Scripps Health
Broomfield, CO – March 3, 2025 – Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company utilizing biomarkers and augmented intelligence (AI) to pinpoint sources of chronic low back pain, has revealed its first commercial agreement with Scripps Health in San Diego, CA. The agreement will make Aclarion’s Nociscan technology available to the largest healthcare system in the San Diego area.
Nociscan combines MR Spectroscopy and AI to identify the sources of chronic low back pain. Through this agreement, the technology will be available for use at Scripps Green Hospital. This will give a larger number of patients in Southern California access to this diagnostic tool.
Dr. Robert Eastlack, an orthopedic surgeon at Scripps Health, emphasized the value of Nociscan. He explained that the technology offers “additional information” that has been “valuable” for himself and his patients. He also noted that patients were previously referred to Beverly Hills for the procedure.
Scripps Health operates five hospitals and 19 outpatient facilities. Each year, the system serves 500,000 patients through its network of 2,600 affiliated physicians. Nociscan will be implemented in both clinical practice and research trials to further the mission to advance spine care.
“Each year at Scripps, we evaluate a large, growing number of patients suffering from chronic low back pain,” said Dr. Eastlack. “I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. Over the last few years, I have referred numerous patients to Beverly Hills for Nociscan. The additional information unique from Nociscan has been valuable to me and my patients. Having Nociscan available at Scripps Green will greatly expand access to my colleagues and our patients in important ways.”
Strategic Benefits of the Agreement
The deal represents a significant step for Aclarion, offering several strategic advantages.
- Market Expansion: The agreement allows Aclarion to enter the Southern California healthcare market via a deal with a major provider.
- Financial Milestone: For a company with a $2.67 million market cap, this deal with a system as large as Scripps represents an important commercial advance.
- Recurring Revenue: The deal aligns with Aclarion’s SaaS (Software as a Service) business, potentially generating recurring revenue.
- Existing Demand: Prior to the agreement, patients were referred from San Diego to Beverly Hills specifically for Nociscan procedures signifying existing clinical demand for this technology.
The partnership with Scripps Health signifies commercial validation for Aclarion’s technology in tackling the diagnostic challenges of chronic low back pain. Moreover, this agreement could set a precedent for similar partnerships with other metropolitan healthcare systems.
Chronic low back pain is a global problem affecting an estimated 266 million people worldwide, and Nociscan directly addresses this issue.
